BPC-157 Research Guide: Mechanisms, Applications, and Preclinical Data

By Justin Cartier

This guide is part of our broader overview of peptides for healing and recovery.

BPC-157 is a synthetic peptide built from 15 amino acids, and researchers study it mostly for healing. Tendon repair and gut protection are the headline uses. The sequence isn’t invented from scratch either. It’s copied from a body-protective compound that scientists first pulled out of human gastric juice back in the early 1990s.^[1]

Research use only: BPC-157 is a research compound, not a medicine, and is not for human use.

Few peptides have been run through rodent healing models as often as this one. Hundreds of studies cover tendon repair, stomach ulcer recovery, new blood vessel growth, and brain protection. This guide walks through what the peer-reviewed work actually shows. We’ll cover the sequence and origin, the three signaling routes most often tied to its repair effects, the rat tendon and gut models that built its name, what the data say about heart, liver, and fat, the open questions in humans, and how to vet material before you buy it.

What is BPC-157?

It’s a synthetic 15-amino-acid peptide that copies one fragment of a natural body protection compound found in human stomach juice. The name is literal: BPC stands for body protection compound. In the original papers its full name is “pentadecapeptide BPC 157,” and its trial code is PL 14736. Here’s the unusual part. It survives stomach acid, so the earliest rat studies could test it three ways at once: by mouth, by injection, and on the skin. It usually ships as a lyophilized white powder, gets mixed with bacteriostatic water, and is checked by HPLC and mass spectrometry against its expected weight near 1,419 Da.

The first descriptions came out of the Sikiric lab in Zagreb. A Sikiric review in Current Pharmaceutical Design describes it as a stable gastric pentadecapeptide and anti-ulcer agent, tested across roughly twenty different injury models.^[1] No oral LD50 has turned up at any dose anyone has tried. That safety margin is a big reason interest held steady through three decades of animal work.

How BPC-157 works: studied mechanisms

Three systems do most of the heavy lifting in the repair data: nitric oxide, the VEGF blood-vessel pathway, and direct growth signals at connective-tissue cells. None of the three is fully mapped. Each one rests on its own pile of rodent and cell studies. The anti-inflammatory effects that show up in so many models look like a downstream result of these signals, not a direct hit on immune messengers.

Start with nitric oxide. The peptide acts upstream of eNOS, the enzyme that makes NO inside blood vessels. A 2020 report in Scientific Reports from Hsieh and colleagues shows it can drive NO production, probably through the Src-Caveolin-1-eNOS pathway.^[2] Repair needs good local blood flow, so this route turns up again and again across the tendon and gut work.

The VEGF pathway is the second recurring theme. The same Taiwan group, writing earlier in the Journal of Molecular Medicine, reported it acts through the VEGFR2-Akt-eNOS pathway, which drives new capillary growth and ties the blood-vessel and blood-flow effects together.^[3] The Zagreb group’s own work, a muscle and tendon healing study led by Brcic, found it lifting new vessel growth by raising VEGF right in the injured tissue.^[4]

The third strand is the most hands-on. In culture, tendon fibroblasts exposed to the peptide show stronger cell migration, more growth, and better cell survival under stress. Skin and gut fibroblasts behave the same way, and collagen-building markers climb. That lines up neatly with the tissue repair seen in live animals. No single receptor has been pinned down. One working idea is that its push on nitric oxide and nearby growth factor signaling is the thread connecting everything.

Is BPC-157 a growth hormone?

No. It’s not a growth hormone, and it’s not a growth-hormone releaser either. It doesn’t bind the GHRH receptor or the ghrelin receptor (GHS-R1a), the two routes that growth-hormone peptides like CJC-1295 and ipamorelin use. People lump them together because suppliers file them all under “regenerative,” but the mechanisms aren’t related.

This matters at the design stage. Pair this peptide with a growth-hormone releaser and you’re testing two separate pathways, not one combined mechanism. So credit any muscle-building signal carefully, because it could be coming from either side.

BPC-157 effects on tendon healing

Tendon healing is the use that made its name. In cut rat Achilles tendon studies, treated animals reattached faster, gained strength by week two, and got back to using the limb earlier than untreated controls. A rat Achilles study by Krivic and colleagues reports it promoted tendon-to-bone healing and pushed back against the damage corticosteroids cause. That result is one of the most repeated in the whole rodent literature.^[5]

The muscle-and-joint research reaches well past the Achilles model. Cut knee ligament (MCL) studies in rats came back with better functional recovery scores. Crushed thigh and calf muscle recovered fiber structure faster. Broken-bone models showed quicker callus formation on micro-CT, gum-ligament repair improved in models of gum disease, and a cut ACL saw strength drift back toward normal. Different tissues, same direction.

The gap is human data. As of 2026 there’s no completed Phase 3 trial in tendon or ligament injury, and the FDA hasn’t granted any treatment use. It stays in research settings only.

Gastrointestinal research applications

Since it traces back to a gastric juice protein, its biggest evidence base sits in the gut. NSAID-driven ulcers from indomethacin and aspirin, colitis, inflammatory bowel models, gastric fistula, short bowel syndrome, alcohol-burn injury, surgical leak models: across all of them it has steadily shown protection or faster lining repair against untreated controls. That repeatability, lab after lab, is the strongest part of the dataset. The Zagreb group also reported small pilot data in interstitial cystitis patients under the PL 14736 code, one of the few human safety readouts on record.

One practical note. It stays active when given by mouth, which is rare for a peptide and comes straight from that stomach-acid stability. So researchers can study lining repair without putting an animal through an injection. You’ll see mentions of BPC-157 cream for knee pain online, but controlled trials haven’t backed those, and no approved human use exists.

Heart, liver, and metabolic effects in preclinical data

Three questions come up over and over: the heart, the liver, and fat. The evidence is animal-only and narrow, but it points in consistent directions.

Rodent heart studies haven’t flagged harm at doses from roughly 10 to 500 micrograms per kilogram, the usual research band. A handful of papers report protection in chemically induced heart-muscle injury, credited to the same VEGF and vessel mechanisms behind the tendon results. No human heart safety dataset exists.

Liver work tells a similar story. In damage models from carbon tetrachloride, acetaminophen, and stress, injury markers like ALT and AST tend to come down. None of that proves the peptide protects the liver in any clinical sense. It shows a direction in animals, and that’s all.

Fat loss is the most over-claimed result on the internet. The published data simply don’t show it burning fat. There’s no weight effect here like you get with GLP-1 drugs, growth-hormone releasers, or AOD-9604. Treat “fat-burning” claims as marketing, not science.

Routes of administration in rodent studies

Published rodent studies lean on four routes: an injection into the belly cavity, an injection into muscle, oral gavage, and topical cream or ointment. Each one produces a measurable effect in the target tissue, which is unusual for a peptide and part of why it caught on as a research tool. Subcutaneous injection shows up too. Doses in the literature cover an enormous span, from 10 nanograms per kilogram all the way to 500 micrograms per kilogram, depending on the model.

Legal status and safety considerations

BPC-157 is legal to buy and use for laboratory research in Canada and the United States, but it is not approved for any medical use. In April 2023 the FDA added it to its 503A “do not compound” list, which stops US compounding pharmacies from preparing it for patients but does not touch research-chemical sales. For the full breakdown of what “legal for research” actually means when buying peptides in Canada, see our peptide legal framework and supplier guide.

The preclinical safety signals are mild. No oral LD50 has shown up at any tested dose, and year-long rat studies haven’t found whole-body toxicity at standard research doses. The real limit isn’t a rodent warning sign. It’s the absence of human safety data.

What Happens If You Skip BPC-157 Purity Verification

Skipping purity verification on BPC-157 means trusting that a vial of white powder actually contains what the label says, and that trust can quietly wreck a study.

BPC-157 is a 15-amino-acid pentadecapeptide with an expected molecular weight near 1,419 Da. That’s a small enough molecule that a synthesis error, like a missing residue, an incomplete coupling step, or a degraded batch, is easy to hide inside something that still looks like ordinary peptide powder. An incomplete or truncated version of the sequence can still show some biological activity, so a tendon-fibroblast migration assay or a VEGF expression readout might come back “positive” without actually testing full-strength BPC-157. The data looks usable. It isn’t testing what you think it’s testing.

Leftover synthesis byproducts or bacterial endotoxin cause a second, sneakier problem. Either one can trigger inflammation in cell culture or animal models that has nothing to do with the peptide itself, and get logged as a treatment effect instead of contamination. A batch that degrades faster than its label claims creates a third problem: silent under-dosing in any study that runs more than a few days, which flattens a real effect until it reads as noise.

None of this shows up by eye. Independent HPLC testing (separating and quantifying related compounds by purity) and mass spectrometry (confirming the batch’s actual mass against the expected ~1,419 Da) catch it, but only when an outside lab runs the test rather than the manufacturer’s own quality control.^[6] A certificate that describes “typical” purity for a product line, instead of the specific vial you received, doesn’t protect against any of the three problems above.

Reviv Peptides supplies BPC-157 at 10 mg per vial with a batch-specific third-party COA, HPLC purity at 99 percent or higher, and mass-spec confirmation of the expected weight. View the BPC-157 10mg product page, or compare it with the BPC-157 and TB-500 Wolverine Stack if you’re studying both pathways at once.

BPC-157 questions

Is BPC-157 a growth hormone?

No. It doesn’t bind the GHRH receptor or the ghrelin receptor. It’s a healing pentadecapeptide that works through nitric oxide and VEGF signaling, not the growth-hormone axis.

Does BPC-157 affect the liver?

In rodent liver-damage models it lowers ALT and AST rises and speeds recovery of liver structure against untreated controls. There’s no human data proving it protects the liver in any clinical sense.

Can BPC-157 burn fat?

The published rodent data don’t support it as a fat-loss peptide. It’s a tissue repair compound, and “fat-burning” claims aren’t grounded in the peer-reviewed work.

Does BPC-157 affect your heart?

Rodent heart studies haven’t shown harm across a wide dose range. A few papers report protection in chemically induced heart injury, credited to nitric oxide and blood-vessel mechanisms. No human heart safety data exists.

Is BPC-157 legal?

It’s legal in Canada and the United States as a research-only chemical. Neither Health Canada nor the FDA has approved it for treatment. The FDA placed it on the 503A “do not compound” list in April 2023, which limits pharmacy compounding but doesn’t touch research-chemical sales.

Key data point: in repeated rat tendon and muscle studies, the peptide sped repair and improved strength and function, and the effect tracked with nitric-oxide-driven vessel growth and higher VEGF in the injured tissue.^[4][5]

Summary

BPC-157 sits in an odd spot among research peptides. The animal data are large, they repeat across labs, and they hold a steady direction, especially for tendon repair and gut wound healing. The human data are basically absent. The mechanism story keeps circling nitric oxide, VEGF, and growth-factor signaling, yet no single receptor has been nailed down. For a researcher, that makes it a genuinely useful tool in repair models and nothing more than that. Source it carefully, dose it against the rodent literature instead of internet claims, and treat every human claim as unproven until a real trial says otherwise.

Sources: [1] Stable gastric pentadecapeptide BPC 157 review, PubMed. [2] BPC 157 and the Src-Caveolin-1-eNOS pathway, PubMed. [3] BPC 157 angiogenesis via VEGFR2 activation, PubMed. [4] BPC 157 and angiogenesis in muscle and tendon healing, PubMed. [5] BPC 157 promotes tendon-to-bone healing in a rat Achilles model, PubMed. [6] Reference standards for synthetic peptide therapeutic quality, PMC.

Justin Cartier

The Reviv Peptides Research Team is a collective of science writers and researchers dedicated to producing evidence-based, peer-reviewed-grade content about research peptides. Our work focuses on molecular mechanisms, receptor pharmacology, and preclinical data — including GLP-1/GIP/glucagon incretin biology, growth hormone axis peptides (GHRH analogs and ghrelin-receptor secretagogues), mitochondrial-derived peptides (MOTS-c, SS-31), tissue-repair peptides (BPC-157, TB-500, GHK-Cu), and nootropic peptides (Semax, Selank). All content is written in a strict preclinical/laboratory context; none of our editorial material is intended as medical advice. Every guide is reviewed for scientific accuracy against published peer-reviewed literature.